These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33318558)

  • 1. Fluorescent ligands for dopamine D
    Allikalt A; Purkayastha N; Flad K; Schmidt MF; Tabor A; Gmeiner P; Hübner H; Weikert D
    Sci Rep; 2020 Dec; 10(1):21842. PubMed ID: 33318558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR
    J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BOPPY-based novel fluorescent dopamine D
    Elek M; Dubiel M; Mayer L; Zivkovic A; Müller TJJ; Stark H
    Bioorg Med Chem Lett; 2022 Mar; 59():128573. PubMed ID: 35063632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors.
    Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L
    Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism.
    Lane JR; Abramyan AM; Adhikari P; Keen AC; Lee KH; Sanchez J; Verma RK; Lim HD; Yano H; Javitch JA; Shi L
    Elife; 2020 Jan; 9():. PubMed ID: 31985399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D
    Shaik AB; Boateng CA; Battiti FO; Bonifazi A; Cao J; Chen L; Chitsazi R; Ravi S; Lee KH; Shi L; Newman AH
    J Med Chem; 2021 Oct; 64(20):15313-15333. PubMed ID: 34636551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RalA employs GRK2 and β-arrestins for the filamin A-mediated regulation of trafficking and signaling of dopamine D2 and D3 receptor.
    Zheng M; Zhang X; Sun N; Min C; Zhang X; Kim KM
    Biochim Biophys Acta; 2016 Aug; 1863(8):2072-83. PubMed ID: 27188791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists.
    Xu W; Wang X; Tocker AM; Huang P; Reith ME; Liu-Chen LY; Smith AB; Kortagere S
    ACS Chem Neurosci; 2017 Mar; 8(3):486-500. PubMed ID: 27801563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
    Zou MF; Keck TM; Kumar V; Donthamsetti P; Michino M; Burzynski C; Schweppe C; Bonifazi A; Free RB; Sibley DR; Janowsky A; Shi L; Javitch JA; Newman AH
    J Med Chem; 2016 Apr; 59(7):2973-88. PubMed ID: 27035329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palmitoylation on the carboxyl terminus tail is required for the selective regulation of dopamine D2 versus D3 receptors.
    Zhang X; Le HT; Zhang X; Zheng M; Choi BG; Kim KM
    Biochim Biophys Acta; 2016 Sep; 1858(9):2152-2162. PubMed ID: 27349735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling Activation-Related Rearrangements and Intrinsic Divergence from Ligand-Specific Conformational Changes of the Dopamine D3 and D2 Receptors.
    Lee KH; Shi L
    J Chem Inf Model; 2024 Mar; 64(6):1778-1793. PubMed ID: 38454785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lentiviral-mediated gene delivery reveals distinct roles of nucleus accumbens dopamine D2 and D3 receptors in novelty- and light-induced locomotor activity.
    Fernandes AR; Easton AC; De Souza Silva MA; Schumann G; Müller CP; Desrivières S
    Eur J Neurosci; 2012 Apr; 35(8):1344-53. PubMed ID: 22394078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of fluorescent ligand binding to dopamine D
    Allikalt A; Laasfeld T; Ilisson M; Kopanchuk S; Rinken A
    FEBS J; 2021 Mar; 288(5):1514-1532. PubMed ID: 32783364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.
    Verma RK; Abramyan AM; Michino M; Free RB; Sibley DR; Javitch JA; Lane JR; Shi L
    PLoS Comput Biol; 2018 Jan; 14(1):e1005948. PubMed ID: 29337986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands.
    Cao Y; Min C; Acharya S; Kim KM; Cheon SH
    Bioorg Med Chem; 2016 Jan; 24(2):191-200. PubMed ID: 26707842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.
    Newman AH; Beuming T; Banala AK; Donthamsetti P; Pongetti K; LaBounty A; Levy B; Cao J; Michino M; Luedtke RR; Javitch JA; Shi L
    J Med Chem; 2012 Aug; 55(15):6689-99. PubMed ID: 22632094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.
    Lane JR; Chubukov P; Liu W; Canals M; Cherezov V; Abagyan R; Stevens RC; Katritch V
    Mol Pharmacol; 2013 Dec; 84(6):794-807. PubMed ID: 24021214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analogues of Arylamide Phenylpiperazine Ligands To Investigate the Factors Influencing D3 Dopamine Receptor Bitropic Binding and Receptor Subtype Selectivity.
    Hayatshahi HS; Xu K; Griffin SA; Taylor M; Mach RH; Liu J; Luedtke RR
    ACS Chem Neurosci; 2018 Dec; 9(12):2972-2983. PubMed ID: 30010318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.